How to Get Rezdiffra (Resmetirom) in District of Columbia

What Is Rezdiffra and Why Does It Matter for DC Residents?

Rezdiffra is the first FDA-approved medication specifically targeting metabolic dysfunction-associated steatohepatitis (MASH), formerly called non-alcoholic steatohepatitis (NASH). For the estimated 6 to 8 million Americans living with MASH-related fibrosis, this drug represents a pharmacologic option where none existed before [1].

The Clinical Evidence Behind Approval

The FDA granted accelerated approval in March 2024 based on the MAESTRO-NASH trial, a phase 3 study enrolling 966 adults with biopsy-confirmed NASH and fibrosis stages F1b through F3. At 52 weeks, 25.9% of patients on the 80 mg dose achieved NASH resolution without worsening fibrosis, compared to 9.7% on placebo (P<0.001). The 100 mg dose produced NASH resolution in 29.9% of patients [1]. Fibrosis improvement of at least one stage occurred in 24.2% of patients on 80 mg and 25.9% on 100 mg, versus 14.2% on placebo [1].

Why DC Access Matters

DC has a high prevalence of metabolic syndrome risk factors. According to CDC data, roughly 32% of DC adults have obesity (BMI ≥30), and the district's Type 2 diabetes prevalence sits near 10%. Both conditions are strongly associated with MASH progression. DC residents now have a clear regulatory and insurance pathway to access resmetirom without leaving the district.

Step-by-Step Prescription Process in DC

Getting Rezdiffra in DC involves a clinical evaluation, diagnostic confirmation, a prescription from a qualified provider, and (for most insured patients) prior authorization. The entire process from first appointment to medication in hand typically spans 2 to 6 weeks.

Step 1: Clinical Evaluation and Diagnosis

A provider must confirm you have MASH with fibrosis stage F2 or F3. This requires either a liver biopsy (the historical gold standard) or a combination of validated non-invasive tests. The AASLD practice guidance now recognizes FibroScan (vibration-controlled transient elastography) and the FIB-4 index as acceptable staging tools in clinical practice [2]. Most hepatologists in DC will order:

• FIB-4 index (calculated from age, AST, ALT, and platelet count)
• FibroScan with CAP (controlled attenuation parameter) for steatosis quantification
• Comprehensive metabolic panel and lipid panel
• HbA1c if not tested within 90 days

A FibroScan liver stiffness measurement between 8.0 and 13.0 kPa generally corresponds to F2, F3 fibrosis. Values above 13.0 kPa suggest F4 (cirrhosis), which falls outside the current approved indication.

Step 2: Prescription and Dose Selection

Rezdiffra dosing is weight-based per the FDA-approved label. Patients weighing less than 100 kg receive 80 mg once daily. Those at or above 100 kg receive 100 mg once daily. Both doses are oral tablets taken with or without food.

The prescriber must document the fibrosis stage, diagnostic method, and clinical rationale. This documentation becomes the backbone of any prior authorization submission.

Step 3: Prior Authorization

Most payers in DC, including Medicaid, require prior authorization. This is standard for specialty medications. The typical turnaround is 5 to 15 business days, though urgent requests can be expedited in 24 to 72 hours.

Who Can Prescribe Rezdiffra in DC?

DC's scope-of-practice laws are among the most permissive in the country for advanced practice providers. This expands the pool of clinicians who can write a Rezdiffra prescription.

Physicians (MD/DO)

Any licensed DC physician can prescribe resmetirom. Hepatologists and gastroenterologists are the most common prescribers, but endocrinologists and internal medicine physicians managing metabolic disease also initiate therapy. No additional DEA scheduling applies because resmetirom is not a controlled substance.

Nurse Practitioners (NP)

DC grants full practice authority to nurse practitioners under the District of Columbia Health Occupations Revision Act. NPs in DC do not need a collaborative agreement with a physician. An NP with appropriate training in hepatology or metabolic disease can independently evaluate, diagnose, and prescribe Rezdiffra.

Physician Assistants (PA)

PAs in DC prescribe under a supervisory agreement with a licensed physician. The supervising physician does not need to be physically present for each encounter, but the agreement must be on file with the DC Board of Medicine. A PA can prescribe Rezdiffra as long as it falls within the scope of their supervisory agreement.

Telehealth Access to Rezdiffra in DC

DC has permanent telehealth parity legislation, making it one of the more telehealth-friendly jurisdictions in the U.S. Resmetirom can be prescribed via a telehealth encounter as long as the provider holds an active DC license.

How Telehealth Prescribing Works

A telehealth visit for Rezdiffra follows the same clinical pathway as an in-person visit. The provider reviews your medical history, interprets lab results and imaging (FibroScan reports can be uploaded digitally), confirms the MASH diagnosis and fibrosis stage, and writes the prescription electronically.

The key requirement: the ordering provider must hold a DC medical license, even if they practice from another state. DC participates in several interstate medical licensure compacts, which streamlines credentialing for out-of-state physicians. NPs benefit from the Nurse Licensure Compact (NLC), though DC-specific endorsement is still required for prescriptive authority.

What Telehealth Cannot Replace

Initial FibroScan or liver biopsy must be performed in person at a facility. DC has multiple hepatology centers offering FibroScan, including those affiliated with MedStar Georgetown, George Washington University Hospital, and several independent gastroenterology practices. Once baseline diagnostics are complete and uploaded to your chart, all follow-up management (dose adjustments, lab review, refill authorizations) can happen by video.

Pharmacy Options in DC

Rezdiffra is a specialty medication. Not every retail pharmacy stocks it. DC residents have two primary dispensing pathways.

Specialty Retail Pharmacies

Most large specialty pharmacy networks (CVS Specialty, Optum Specialty, Accredo) can ship Rezdiffra to DC addresses. Your provider or insurance plan typically designates a preferred specialty pharmacy. If your insurer mandates a specific network, the prescription will be routed there automatically.

Expect to receive a 30-day supply per fill. Specialty pharmacies assign a dedicated patient coordinator who manages refills, tracks prior authorization renewals, and arranges delivery.

503A Compounding Pharmacies

DC-licensed 503A compounding pharmacies can compound resmetirom pursuant to a patient-specific prescription. Under federal law (Section 503A of the Federal Food, Drug, and Cosmetic Act), these pharmacies compound medications based on individual prescriptions rather than manufacturing in bulk [3]. This pathway may offer cost advantages for patients paying out of pocket, though compounded versions are not FDA-approved formulations.

A 503A pharmacy in DC must hold an active DC Board of Pharmacy license. It can ship within DC but interstate shipping follows the pharmacy's state-specific licensure. If you live in DC and want a compounded version, confirm the pharmacy holds the appropriate DC license before filling.

DC Medicaid Coverage and Prior Authorization

DC Medicaid (managed through the Department of Health Care Finance) covers Rezdiffra with prior authorization for the FDA-approved indication: MASH with moderate to advanced hepatic fibrosis (F2, F3) [4].

Documentation for Prior Authorization

The PA request must include:

• Confirmed MASH diagnosis with ICD-10 code K75.81
• Fibrosis stage documentation (F2 or F3) via biopsy report or validated non-invasive test results
• Evidence that the patient does not have decompensated cirrhosis (Child-Pugh B or C)
• Baseline liver function tests (ALT, AST, bilirubin, albumin)
• Prescriber's attestation that the patient has been counseled on lifestyle modifications (diet, exercise, alcohol avoidance)
• Medication history showing no contraindicated drug interactions

Timeline and Appeals

Initial PA decisions in DC Medicaid typically arrive within 10 business days. If denied, the prescriber can submit a peer-to-peer review request, which must be scheduled within 5 business days of the denial. A formal appeal can follow if the peer-to-peer does not reverse the decision. The DC Department of Health Care Finance publishes appeal procedures on its website.

Commercial Insurance in DC

Most commercial plans in DC (CareFirst BlueCross BlueShield, Kaiser Permanente Mid-Atlantic, Aetna, UnitedHealthcare) also require prior authorization for Rezdiffra. Coverage criteria mirror the FDA label: biopsy or non-invasive test confirming F2, F3 fibrosis, plus a MASH diagnosis. Copay assistance through Madrigal Pharmaceuticals' patient support program may reduce out-of-pocket costs for commercially insured patients to as low as $0 per month for eligible individuals.

Required Labs and Monitoring

Resmetirom requires specific laboratory monitoring before and during treatment. The FDA label outlines these requirements, and most DC payers enforce them as conditions of ongoing coverage [5].

Before Starting Treatment

• Complete metabolic panel (CMP) including ALT, AST, total bilirubin, and albumin
• Thyroid function tests (TSH, free T4). Resmetirom is a thyroid hormone receptor beta (THR-β) agonist. Baseline thyroid function must be documented.
• Lipid panel. Resmetirom lowers LDL cholesterol by 13 to 16% as a secondary effect [1].
• Pregnancy test for women of childbearing potential. Resmetirom is not recommended during pregnancy.

Ongoing Monitoring

The prescribing information recommends liver function tests at baseline, during dose titration, and periodically thereafter. Most DC hepatologists check ALT and AST at weeks 4, 12, and 24, then every 6 months. Thyroid function should be reassessed if symptoms of thyroid dysfunction develop, though clinically significant thyroid effects have been rare in trial data. In MAESTRO-NASH, TSH elevations above the upper limit of normal occurred in fewer than 2% of treated patients [1].

Dose interruption is recommended if ALT or AST rises above 5 times the upper limit of normal, or if total bilirubin exceeds 2 times the upper limit of normal with concurrent transaminase elevation.

Timeline: From First Visit to Medication in Hand

The realistic timeline for a DC resident seeking Rezdiffra depends on insurance type and whether baseline diagnostics are already completed.

If Diagnostics Are Already Done

Patients who arrive with a recent FibroScan or biopsy report confirming F2, F3 can move quickly. A single telehealth or in-person visit with a qualified prescriber, followed by electronic prescription submission and PA, can get the medication dispensed in 2 to 3 weeks.

If Starting From Scratch

A new patient with suspected MASH but no prior workup should expect:

• Week 1 to 2: Initial consultation, lab orders, FibroScan scheduling
• Week 2 to 4: FibroScan or biopsy performed, results reviewed
• Week 3 to 5: Prescription written, PA submitted
• Week 4 to 6: PA approved, specialty pharmacy ships medication

Total elapsed time: roughly 4 to 6 weeks. Delays are most common at the PA stage, particularly with Medicaid managed care organizations that require additional documentation rounds.

Transferring a Prescription to DC

If you already have an active Rezdiffra prescription in another state, transferring it to a DC pharmacy is straightforward. Federal law permits one transfer of a non-controlled prescription between pharmacies. Since resmetirom is not a controlled substance, a single transfer is allowed.

Your current pharmacy can transfer the prescription electronically or by phone to a DC-licensed specialty pharmacy. The receiving pharmacy will verify your DC address and insurance coverage. If your new DC insurance requires its own prior authorization, your prescriber will need to submit a new PA, even if you had an active authorization in your previous state. PA approvals do not transfer between state Medicaid programs.

Alternatively, your new DC provider can write a fresh prescription based on your existing medical records. This is often faster than waiting for an inter-pharmacy transfer, especially when switching insurance plans simultaneously.